
Royalty Pharma (RPRX) Stock Forecast & Price Target
Royalty Pharma (RPRX) Analyst Ratings
Based on 17 analyst ratings
Buy
Strong Buy 65%
Buy 24%
Hold 12%
Sell 0%
Strong Sell 0%
Royalty Pharma (RPRX) has been analyzed by 17 analysts, with a consensus rating of Buy. 65% of analysts recommend a Strong Buy, 24% recommend Buy, 12% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.
This aggregate rating is based on analysts' research of Royalty Pharma and is not a guaranteed prediction by Public.com or investment advice.
This aggregate rating is based on analysts' research of Royalty Pharma and is not a guaranteed prediction by Public.com or investment advice.
Royalty Pharma (RPRX) Analyst Forecast & Price Prediction
Get the latest Royalty Pharma (RPRX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis
Start investing in Royalty Pharma (RPRX)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Royalty Pharma (RPRX) Forecast
Analysts have given Royalty Pharma (RPRX) a Buy based on their latest research and market trends.
According to 17 analysts, Royalty Pharma (RPRX) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.
Wall Street analysts have set a price target of $38.50, reflecting a 0.00% increase from the current stock price.
Financial analysts have set a price target of $38.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.